Synaptogenix (NASDAQ:TAOX – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.
Synaptogenix Stock Down 8.6%
NASDAQ:TAOX opened at $8.40 on Friday. Synaptogenix has a one year low of $1.84 and a one year high of $11.98. The company has a market capitalization of $11.68 million, a P/E ratio of -0.83 and a beta of 1.87.
Synaptogenix (NASDAQ:TAOX – Get Free Report) last posted its quarterly earnings results on Friday, August 15th. The company reported ($11.26) EPS for the quarter.
About Synaptogenix
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Further Reading
- Five stocks we like better than Synaptogenix
- What Are Treasury Bonds?
- 3 Restaurant Stocks That Will Outperform in Q3 and Q4
- What is the S&P/TSX Index?
- The Midstream Energy Play That Keeps Powering Higher
- Investing in the High PE Growth Stocks
- Ethereum Near All-Time High: 3 Stocks Stacking ETH in Treasuries
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
